【藥品訊息】 Spiriva 吸入劑 衛教單張

氣喘或慢性阻塞性肺病 Maintenance treatment of bronchospasm associated with COPD (bronchitis and emphysema), reduction of COPD exacerbations.

Tiotropium bromide is a long-acting, specific antagonist at muscarinic receptors. Blockade of muscarinic receptor subtypes M1 and M3, facilitating bronchodilation and reducing mucus secretion. The effect was dose dependent and lasted longer than 24h.

Approximately 40% of the inhaled dose is deposited in the lungs, the target organ, the remaining amount being deposited in the gastrointestinal tract; systemic absorption may occur from lung; Protein binding 72%; elimination half-life 5-6 days.

patients with a history of hypersensitivity to atropine or its derivatives, e.g. ipratropium or oxitropium or to any component of this product.

C

Excretion in breast milk unknown/use caution

Dry mouth (most common), upper respiratory tract infection, sinusitis; pharyngeal irritation, headache, insomnia, constipation, palpitations, rash, dysuria and urinary retention.

The delivered dose is 2.5 mcg tiotropium per puff (2 puffs per dose). Administer once daily at the same time each day.